Summit Therapeutics (SMMT) Change in Acquisitions & Divestments (2023 - 2026)

Summit Therapeutics (SMMT) has 4 years of Change in Acquisitions & Divestments data on file, last reported at $448.8 million in Q2 2026.

• Quarterly Change in Acquisitions & Divestments rose 197.59% year-over-year to $448.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $626.1 million (up 1.26% YoY) and the FY2025 annual result came in at $311.3 million, down 36.44% from the prior year.
• Change in Acquisitions & Divestments rose to $448.8 million in Q2 2026, from $177.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $448.8 million in Q2 2026 to a low of $38.2 million in Q2 2023.
• A 4-year average of $148.7 million and a median of $112.9 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The widest YoY moves for Change in Acquisitions & Divestments: up 284.66% in 2024, down 32.37% in 2024.
• Tracing SMMT's Change in Acquisitions & Divestments over 4 years: stood at $60.6 million in 2023, then surged by 284.66% to $233.0 million in 2024, then plunged by 35.27% to $150.8 million in 2025, then surged by 197.59% to $448.8 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $448.8 million (Q2 2026), $177.3 million (Q1 2026), and $150.8 million (Q2 2025), per Business Quant data.